

## Index

- A**
- ability to pay, 71, 178, 253, 258, 268
  - ABL facility. *See* asset based lending facility
  - accelerated depreciation, 119
  - accountants, 164, 265, 271
  - accounting, 11, 31, 45, 164, 195, 213–214, 271
  - accounts payable, 118, 121, 123–124
  - accounts receivable, 121–123, 180, 182, 188
  - accretion/(dilution) analysis, 251, 258, 267–269
  - accretive, 267–268
  - accrued liabilities, 121, 124, 145
  - acquisition currency, 76
  - acquisition-driven growth, 19
  - acquisition financing, 76–78, 80
  - adjusted income statement, 43, 60–61, 64, 103–104
  - adjustments
    - balance sheet, 203, 209–214, 226
    - capital expenditures, 205
    - capital structure changes, 33
    - management projections, 116, 199
    - mid-year convention, 151
    - non-recurring items, 13, 23, 41–43, 60–62, 80, 102–104, 115, 205
    - purchase price and financing structure, 198, 237
    - recent events, 23, 43–44, 80, 115
    - synergies, 80, 91–92
    - year-end discounting, 152
  - administrative agent, 213
  - administrative agent fee, 213, 222
  - advisor, 75, 78–79, 164, 195, 198, 236, 251–252, 255–259, 261–265, 267–268, 270, 272, 276–278, 281–282
  - affiliate, 79, 193
  - affirmative covenants, 192, 275
  - Alacra, 130
  - all-cash transaction, 77, 85, 100
  - amortization
    - acquisition-related, 34, 45
    - intangible assets, of, 119–120
    - deferred financing fees, of, 203–204, 213, 222
    - term loan, 183, 218, 220, 226
    - schedule, for term loans, 183, 184, 218. *See also* depreciation & amortization (D&A)
  - amortizing term loans, 183. *See also* term loan A
  - announcement
    - earnings, 21, 23–24, 40–42, 55
    - transaction, 44, 73, 79–80, 83, 86–87, 89–91, 96–98, 100, 105, 278
  - annual report. *See* Form 10-K
  - antitrust, 258–259, 275, 279
  - arranger, 162, 165–166, 186, 213
  - asset base, 37, 121, 161–162, 168, 171
  - asset based lending (ABL) facility, 180, 182–183
  - asset sale
    - gains on, 41, 61, 103
    - limitations on, 194
    - losses on, 41
    - term loan prepayment, 218
    - transaction, 212, 274, 276

- attorneys, 271  
auction, 76–77, 93, 95, 164,  
251–280. *See also* broad auction  
and targeted auction
- B**  
back-end short form merger, 280  
balance sheet, 22–23, 25, 32, 44,  
58–59, 80, 254  
in LBO analysis, 198, 201–204,  
210–214, 224, 226–227, 241  
bank book, 166–167  
bank debt, 161, 165–167, 168,  
178–188, 190–194, 221–222,  
228, 230  
bank lenders, 165–166, 183, 189  
bank meeting, 166  
bankruptcy, 33, 161, 171, 182–184,  
188–189  
Barra, 130  
barriers to entry, 169, 171  
Base Case, 3, 116, 140–141, 145,  
157, 199, 230, 232  
Base Rate, 181, 190  
basic shares outstanding, 22–23, 25,  
27–30, 54, 57–58, 101, 137  
basket, 193–194  
benchmarking analysis  
comparable companies analysis, 11,  
13, 19–20, 23, 27, 40, 48–49, 55,  
62, 65–69  
precedent transactions analysis, 73,  
81, 92–93, 105–106  
benchmark rate. *See* LIBOR and Base  
Rate  
beta ( $\beta$ ), 127–131, 147–148  
relevering, 130, 148  
unlevering, 130, 147  
bidders. *See* prospective buyers  
bidding strategy, 196  
Bloomberg, 24–25, 81, 128–129, 147,  
216  
board approval, 256, 272, 276, 278  
board of directors, 79, 82, 97, 168,  
257, 262, 277–278, 281–282  
bond investors, 166–167  
book value  
assets, 119–120  
equity, 209, 212  
bookrunners, 165  
borrower, 19, 161, 178, 180–184,  
186–194, 218, 221  
borrowing base, 180, 182–183  
breakage costs, 33, 209  
breakeven pre-tax synergies, 268  
breakup fee, 275  
bridge loans, 165, 186, 213  
bring-down provision, 274–276  
broad auction, 251–252, 254,  
257–258  
advantages and disadvantages, 254  
business disruption, 33, 251, 254,  
257, 282  
business profile, 16–18, 20, 92  
buy-side advisory, 116, 162, 164,  
196, 256, 263
- C**  
CA. *See* confidentiality agreement  
CAGR. *See* compound annual growth  
rate  
calendarization of financial data, 13,  
27, 40–41, 51  
calendar year, 21, 40–41, 45, 135  
call date, 127, 191  
call premium, 191  
call price, 127, 191  
call protection, 188, 191, 222  
call schedule, 127, 191  
callable bond, 127  
capex. *See* capital expenditures  
capital asset pricing model (CAPM),  
127–131, 147–148  
capital expenditures (capex), 22, 25,  
45, 62, 104, 109, 111, 139, 179,  
181, 201, 204–206. *See also*  
growth capex and maintenance  
capex  
in coverage ratios, 38, 63, 230  
in free cash flow, 115, 117–121,  
140, 142–143  
in leverage ratios, 38

- limitations on, 192–193, 274
- low requirements, for LBOs, 168, 170
- projection of, 120–121, 143
- Capital IQ, 20, 42, 75
- capital markets, 39, 162
  - conditions, 18, 76, 94–95, 162, 165, 179, 253, 259
  - transactions, 23–24, 55, 280
- capital structure, 11, 32–35, 45, 111, 115, 139, 146, 162
  - effects of changes in, 33
  - LBO financing, 162, 164, 169, 171, 175–178, 183, 185, 187, 199, 215, 222, 230, 236, 263. *See also* financing structure
  - optimal capital structure, 126
  - target capital structure, for WACC, 124–127, 130, 146–149
- capitalization, 125, 147, 230, 237
- capitalization ratio, 37–38, 62–63, 125, 146, 230
- CAPM. *See* capital asset pricing model
- caps, 165, 186
- cash and stock transaction, 85, 88
- cash available for debt repayment, 111, 161, 170, 174–175, 215–216, 221–222
- cash flow generation, 46, 52, 126, 162, 166, 168–171, 173, 175, 195, 221
- cash flow statement 23, 25, 34, 42, 62, 104, 119, 121
  - in LBO analysis, 198, 203–207, 213, 215–216, 222, 224, 226, 228–229, 242
- cash flow sweep, 198, 218, 228
- cash interest expense, 222
- cash on hand, 123–124
  - funding source, 209, 211, 280
- cash return, 172–176, 233
- CDO. *See* collateralized debt obligation funds
- certainty of closing/completion, 77, 165, 251, 282
- change of control, 83, 194, 279
- CIM. *See* confidential information memorandum
- closest comparables, 12–13, 48–49, 54, 65, 69, 147
- closing, of transaction, 87, 100, 165, 167, 186, 209, 216, 255–257, 264, 274, 276, 278–280
- closing conditions, 273, 275–276, 278, 280
- club deal, 187
- clubbing, 262
- COGS. *See* cost of goods sold
- collar, 87
- collateral, 171, 178, 182, 184, 187–190, 192–193
- collateral coverage, 166, 188
- collateralized debt obligation (CDO) funds, 5, 166, 179, 184
- commitment fee, 181, 186, 218, 222
- commitment letter, 162, 165, 186, 201
- commodity, 18, 177, 182
- common stock, 27, 30, 178, 187–188
- comparable companies analysis, 11–69, 71–73, 75, 81–83, 89, 93, 108–109, 112, 116, 123, 125, 135, 138–140, 147–148, 151, 157, 236, 253, 258, 278. *See also* Contents, pages vii–viii
  - key pros and cons, 52
- Competition Bureau, 279
- competitors, 12, 16, 20, 53, 110, 114, 140, 252, 254, 260, 266, 262
- compound annual growth rate (CAGR), 36, 64–65, 140
- confidential information memorandum (CIM), 53, 110, 114, 166, 198–199, 201, 204, 256, 259–261, 263–264, 267
  - sample, 261
- confidentiality agreement (CA), 89, 256–257, 261–263, 281
  - provisions, 261–262
- consensus estimates, 21, 23–24, 36, 44, 49, 54–55, 64–65, 116–118, 120, 140, 142. *See also* First Call and IBES

- consultants, 164, 169–170, 263, 270–271  
contact log, 262  
contractual subordination, 189  
control premium, 71, 77  
conversion price, 30–32  
convertible securities, 27–32, 43, 57–58  
corporate finance, 162  
corporate website, 15–16, 22, 24, 55, 81, 98  
cost of capital, 111, 129, 177–178, 180, 184, 186, 190, 216, 236, 253, 259. *See also* weighted average cost of capital (WACC)  
cost of debt, 31, 125–127, 146, 149, 175  
cost of equity, 125–131, 147–149. *See also* capital asset pricing model (CAPM)  
cost of goods sold (COGS), 34–35, 119, 122–124  
    non-recurring items in, 61  
    projection of, 117–118, 142  
cost structure, 17–18, 169  
coupon, 30, 127–128, 183–188, 190–191, 215–216, 218, 221–222  
covenant-lite loans, 192  
covenants, 166–167, 177, 181–182, 184, 188, 190, 192–194, 201  
    in definitive agreements, 273–275  
    incurrence, 185, 192, 194  
    maintenance, 178, 183, 185, 192–194  
coverage ratios. *See* interest coverage  
credit agreement, 181, 183, 185, 192–194, 218  
credit committee, 165, 195, 201, 266  
credit crunch, 76–77, 94, 109, 161, 165, 216  
credit markets, 77, 161  
credit profile, 16, 19, 27, 37–38, 126, 166, 178, 183, 192–193  
credit ratings, 24–25, 27, 39, 55, 126, 127, 181  
    ratings scales, 39  
credit statistics, 62–63, 126, 166, 195, 230, 232, 237  
cultural fit, 251, 258  
current assets, 121–124, 145, 182, 203  
current liabilities, 121–124, 145, 203  
current report. *See* Form 8-K  
current stub, 40, 61  
current yield, 127, 146  
customers, 16–18, 22, 53, 110, 114, 140, 170, 254, 260–261, 266, 282  
cyclical sectors, 16, 115, 117, 132, 177, 182  
cyclicality, 93, 95, 111, 118, 126, 131, 205
- D**  
D&A. *See* depreciation & amortization  
data room, 53, 198, 252, 256, 262, 264–266, 270–272, 281  
    general index, 266  
days inventory held (DIH), 123, 140, 145  
days payable outstanding (DPO), 123–124, 140, 145  
days sales outstanding (DSO), 122–124, 140, 145  
DCF. *See* discounted cash flow analysis  
D/E. *See* debt-to-equity  
deal dynamics, 72, 76–77, 80, 93, 95, 106  
deal terms, 20, 80, 83, 278, 281–282  
debt capital markets, 5, 127, 162, 195  
debt repayment, 169, 173–175, 195, 203, 215, 232, 253  
debt schedule, 199, 203, 205, 215–224, 226, 243  
debt securities, 15, 72, 77, 79, 81, 114, 184

- debt-to-EBITDA, 37–38, 63,  
193–194, 230
- debt-to-equity (D/E), 130,  
146–149
- debt-to-total capitalization, 37–38,  
62–63, 125, 146, 230
- DEF14A. *See* proxy statement
- default, 39, 127, 181, 188, 192
- deferred financing fees, 203, 213–214,  
222
- definitive agreement, 78, 80, 83, 87,  
96, 106, 186, 255–256, 258,  
267, 270–273, 276–280
  - key sections, 274–276
- DEFM14A. *See* merger proxy
- Delaware, 257
- Department of Justice (DOJ), 279
- depreciation, 119–120, 204, 206
- depreciation & amortization (D&A),  
34, 45, 62, 118–120, 142–143,  
203, 269
  - projection of, 119–120, 143
- description of notes, 167
- DIH. *See* days inventory held
- dilutive, 28–31, 267–268
- discount factor, 112, 134–135
  - with mid-year convention, 135,  
153
  - with year-end discounting, 135
- discount rate, 109, 111–112, 124,  
134–135, 137, 171. *See also*  
weighted average cost of capital  
(WACC)
- discounted cash flow (DCF) analysis,  
20, 51–52, 109–157, 161, 203,  
236, 258, 278, 281. *See also*  
Contents, page viii–ix
  - key pros and cons, 139
- distressed companies, 164
- distressed debt funds, 166
- distribution channels, 16–18, 53,  
71
- dividend recapitalization,  
176–177
- dividend yield, 19, 27, 37, 62
- DOJ. *See* Department of Justice
- Downside Case, 116, 201, 218
- DPO. *See* days payable outstanding
- drop dead date, 275
- DSO. *See* days sales outstanding
- due diligence, 110, 164, 166,  
169–170, 198–199, 201, 252,  
256–258, 264–267, 270–272,  
274, 276, 278, 281–282
- E**
- earnings before interest after taxes  
(EBIAT), 19, 36, 119–122, 143,  
145
- earnings before interest and taxes  
(EBIT), 18–19, 25, 34–35
  - projection of, 118, 142–143
- earnings before interest, taxes,  
depreciation and amortization  
(EBITDA), 18–19, 25, 34, 35
  - projection of, 118, 142
- earnings call transcripts, 15, 55, 110,  
114
- earnings per share (EPS), 19, 21, 23,  
25, 30, 34, 36, 42, 44–45, 55, 62,  
64–65, 89–90, 93, 105, 267–268
- EBIAT. *See* earnings before interest  
after taxes
- EBIT. *See* earnings before interest and  
taxes
- EBITDA. *See* earnings before interest,  
taxes, depreciation and  
amortization
- EDGAR. *See* Electronic Data  
Gathering, Analysis, and  
Retrieval system
- effective tax rate, 119
- Electronic Data Gathering, Analysis,  
and Retrieval system (EDGAR),  
22
- EMM. *See* exit multiple method
- end markets, 16–17, 22, 53, 71, 114,  
169
- end-of-year discounting. *See* year-end  
discounting

- endowments, 163  
engagement letter, 165  
enterprise value, 11, 13, 18, 20, 27,  
44–45, 64, 69, 81, 89–90, 95–97,  
109, 111, 135–137, 153–154,  
157, 162, 170, 187, 207  
at exit, in LBO, 173–175, 232  
calculation of, 32–33, 57–59, 85,  
88–89, 101–102  
implied, 50–51, 69, 106, 108, 207,  
209  
enterprise value multiples, 33, 44–47,  
64, 90  
enterprise value-to-EBIT (EV/EBIT),  
44–46, 64, 90, 104  
enterprise value-to-EBITDA  
(EV/EBITDA), 11, 13, 44–46,  
49–50, 64, 69, 73, 90, 93, 104,  
106, 151  
enterprise value-to-sales (EV/sales),  
44, 46, 64, 90, 104  
EPS. *See* earnings per share  
equity contribution, 161, 171–176,  
178, 185, 187–188, 195,  
209–212, 214, 226, 230,  
232–233, 235–236, 267  
equity investors, 19, 37, 126–128  
equity purchase price, 82, 207, 209,  
212  
equity research analysts, 20, 36, 44,  
65  
equity research reports, 18, 20–21,  
23, 25, 53–55, 89, 91, 98, 110,  
114, 116–117  
equity risk premium, 129. *See also*  
market risk premium  
equity sweetener, 27  
equity value, 13, 18, 20, 24, 27, 33,  
44, 47, 64, 89, 157, 167,  
173–174, 176, 187  
at exit, in LBO, 170, 173–176,  
232–233  
calculation of, 27–32, 57–58,  
81–88, 97, 101  
implied, 50–51, 83, 102, 111,  
136–137, 154  
equity value multiples, 44–45, 47, 90.  
*See also* price-to-earnings (P/E)  
ratio  
equity-linked securities. *See*  
convertible securities  
European Commission, 279  
EV/EBIT. *See* enterprise value-to-EBIT  
EV/EBITDA. *See* enterprise  
value-to-EBITDA  
EV/sales. *See* enterprise value-to-sales  
exchange offer, 78–79, 82, 185, 280  
exercisable, 27–28, 83, 101  
exercise price, 27–30, 50, 57–58  
exit multiple, 132–133, 137, 139,  
152, 157, 172, 176, 232–233,  
235  
implied, 133, 152, 196  
exit multiple method (EMM), 111,  
132–133, 135, 151–154  
exit strategies, 169, 176–177, 185,  
232  
exit year, 172, 196, 232–233, 235  
expenses, 34, 42, 111, 115, 119, 124,  
193  
financing, 213, 269  
non-cash, 34, 119, 203–204, 213,  
222  
transaction, 208–213, 226,  
230
- F**  
face value, 31, 128, 191  
Factiva, 24, 81  
FactSet, 20, 23–24, 129  
FactSet Mergerstat, 75  
fair market value, 212  
fairness opinion, 20, 78–79, 97,  
251–252, 256, 276–279  
screening for comparable  
companies, 20, 53  
screening for comparable  
acquisitions, 75  
FASB. *See* Financial Accounting  
Standards Board  
FCF. *See* free cash flow  
Federal Funds rate, 181

- federal taxes, 42, 119
  - Federal Trade Commission (FTC), 279
  - fee letter, 165
  - fiduciary duties, 254, 257, 278
  - fiduciary termination, 275
  - final bid package, 195, 272–273, 276
  - final bid procedures letter, 256, 272, 276
  - final bids, 256–257, 266, 270, 276–277
  - Financial Accounting Standards Board (FASB), 31
  - financial covenants, 184. *See also* maintenance covenants
  - financial distress, 33, 37–38, 126, 175, 192
  - financial information services, 13, 20–24, 42, 54, 130
  - financial profile, 16, 18–19, 27, 48, 53, 69, 71, 92, 93, 114
  - financial sponsors, 76, 95, 161–173, 175–178, 185, 187–188, 195–196, 199, 201, 205, 232–233, 235–236, 253, 258–260, 262–263, 265, 267, 270, 274
  - financial statistics, 11–13, 15, 18–19, 21, 23, 27, 36, 38, 44–45, 48–49, 53–55, 62, 72–73, 78, 80–81, 89–90, 92–93, 97, 105, 116
  - financing structure, 161–166, 169, 172, 174, 178–180, 182–183, 187, 190, 192, 195–199, 201–206, 208–209, 213, 215, 218, 222, 235, 237, 266–268, 281
    - analysis of, 230–232
    - pre-packaged, 258, 265
  - firm value, 32
  - First Call, 21, 24–25
  - first lien, 178, 182–185, 190–191
  - first priority interest. *See* first lien
  - first round, of auction, 256, 259, 262–269, 272, 277
  - fiscal year, 22, 40–41, 44
  - Fitch Ratings, 19, 21, 24, 39
  - fixed charge coverage ratio, 183, 193–194
  - fixed charges, 193
  - fixed costs, 35, 118
  - fixed exchange ratio, 85–88
  - fixed price. *See* floating exchange ratio
  - fixed rate, 185, 187, 190–191
  - fixed value, 85, 88
  - floating exchange ratio, 85, 87–88
  - floating rate, 181, 184–185, 187, 190, 215
  - football field, 69, 108, 157, 236
  - Form 8-K, 15, 21–25, 40, 44, 55, 79–80, 82–83, 96, 101, 110, 114, 185
  - Form S-4, 44, 79, 81–83. *See also* registration statement
  - Form 10-K, 15, 21–25, 28, 30, 36, 40–42, 54–55, 59, 62, 79–80, 82–83, 97, 101–102, 104, 114, 121, 201
  - Form 10-Q. *See* pages for Form 10-K
  - forward LIBOR curve, 215–216
  - forward multiples, 64, 69
  - free cash flow (FCF), 109–114, 131–133, 135, 139–142, 151, 153, 161, 173, 175, 203, 215–216, 221, 226, 230, 253
    - calculation of, 115
    - projection of, 115–124, 143–146
  - friendly (deal), 76, 95
  - FTC. *See* Federal Trade Commission
  - fully diluted shares outstanding, 27–31, 50, 57–58, 83, 85–86, 89, 101, 136, 207
  - fund (pool of capital), 162–164, 259
- G**
- GAAP. *See* generally accepted accounting principles
  - general partner (GP), 163, 259
  - generally accepted accounting principles (GAAP), 25, 30, 34, 119

- geography, 16, 18, 21, 75  
goodwill, 120, 212  
goodwill created, 209, 211–212  
goodwill impairment, 41, 120  
GP. *See* general partner  
gross margin, 34, 35, 117–118, 142, 199  
gross profit, 18–19, 21, 25, 27, 34  
    projection of, 117–118, 142  
growth capex, 170–171  
growth profile, 16, 19, 27, 36, 114, 170, 253  
growth rates, 13, 18, 19, 27, 36, 48, 64–65, 109, 111–112, 115, 117, 137, 139–141, 157, 233  
guarantees, 181, 189–190, 194
- H**  
Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act), 278–279  
hedge funds, 162–163, 166, 179, 184, 187  
high yield bonds, 81, 165–166, 178–180, 183–188, 190–192, 194, 201, 222  
historical financial data/performance, 19, 21, 27, 36, 53–54, 59, 62, 64, 80, 98, 111, 115–122, 140–143, 145, 166, 169, 199, 205, 250, 253, 260, 278  
holding company (HoldCo), 177, 179, 189–190  
hostile (deal), 76–77  
HSR Act. *See* Hart-Scott-Rodino Antitrust Improvements Act of 1976
- I**  
Ibbotson, 129, 131, 147  
IBES (Institutional Brokers' Estimate System), 21, 24–25  
if-converted method, 28–31  
in-the-money, 27–31, 57–58, 83, 101, 136  
income statement, 13, 23, 25, 32–35, 43–44, 55, 59–61, 64, 102–104, 119–120, 140  
    in LBO analysis, 199–201, 203–204, 213, 215, 218, 221–222, 224–225, 240  
incurrence covenants, 185, 192, 194  
indemnification, 273–276  
indenture, 127, 167, 185, 189, 191, 193–164  
industry, 16, 167, 177, 254, 270, 278–279. *See also* sector  
information statement, 82  
initial bid procedures letter, 256, 262–264, 272  
initial bids, 253, 262, 267  
initial public offering (IPO), 11, 109, 161–162, 167, 170, 176–177  
initiating coverage reports, 20, 23, 117  
insolvency, 33, 126  
institutional investors, 183  
institutional lenders, 163, 165–166  
institutional term loans, 183, 190.  
    *See also* term loan B  
intangible assets, 119–120, 182, 212, 269  
interest coverage, 38, 193  
interest expense, in LBO analysis, 222–224  
interest income, 224  
internal rate of return (IRR), 171–176, 233–236  
intrinsic valuation analysis, 11  
intrinsic value, 109  
inventory, 41–42, 60, 118, 121, 123, 145, 180, 182, 188  
investment banks, 16, 20, 28, 75, 128–129, 162–166, 168, 181, 186, 195, 201, 251–252, 263, 265, 278  
investment decisions, 11, 109, 166, 265  
investment grade, 39  
investment horizon, 162, 170–173, 175–176, 199

investor presentations, 15–16, 20–21,  
110, 114  
IPO. *See* initial public offering  
IRR. *See* internal rate of return  
issuer, 15, 27, 30–32, 39, 44, 79, 82,  
165, 178, 184–195

## J

joint proxy/registration statement,  
78–79  
joint ventures, 193  
junior (ranking), 179, 184–185,  
188–189, 194

## L

large-cap, 65, 69  
last twelve months (LTM), 13, 21, 27,  
38–40, 44–45, 49–51, 54, 59,  
61–64, 69, 73, 80, 89–94, 97,  
104–106, 132, 135, 140, 151,  
157, 206, 209, 235–236, 267  
layering, 194  
LBO. *See* leveraged buyouts  
LBO analysis, 20, 51, 112, 161,  
195–247, 253, 258, 267, 278.  
*See also* Contents, page x  
LC. *See* letters of credit  
lease, 35, 193, 265  
legal counsel, 259, 261, 263, 265,  
273, 277  
letters of credit (LC), 181, 209  
leverage levels, 162, 177–179, 185,  
187, 233, 235, 267  
leverage ratios, 27, 38, 181,  
192–194  
leveraged buyouts (LBO), 161–194.  
*See also* Contents, pages ix–x  
leveraged loan, 171, 183, 185.  
*See also* bank debt  
levered beta, 128, 130  
predicted, 55, 148. *See also* Barra  
levered free cash flow, 111, 161, 175.  
*See also* cash available for debt  
repayment  
LexisNexis, 24, 81

liabilities, long-term, 201, 203, 215,  
224, 226  
LIBOR. *See* London Interbank  
Offered Rate  
LIBOR floor, 216  
limited partners (LPs), 163, 172, 176,  
259  
liquidity, 123–124, 181, 209  
London Interbank Offered Rate  
(LIBOR), 146, 216  
long-term growth rate, 36, 117  
LPs. *See* limited partners  
LTM. *See* last twelve months

## M

M&A. *See* mergers & acquisitions  
MAC/MAE. *See* material adverse  
change/effect  
maintenance capex, 170  
maintenance covenants, 178, 183,  
185, 192–194  
make-whole provision, 191  
management buyout (MBO), 168, 280  
Management Case, 116, 138, 199  
management discussion & analysis  
(MD&A), 22, 41, 55, 97, 104,  
114, 120–121, 260–261  
management presentation, 53, 198,  
256, 259, 262, 264–265,  
270–271, 281  
sample, 264  
mandatory amortization/repayment,  
185, 199, 215–216, 218, 226  
marginal tax rate, 42, 55, 62, 115,  
118–119, 125, 127, 130, 143,  
147–148, 175–176, 224  
margins, 13, 19, 27, 35, 45, 48, 109,  
111–112, 115, 117–118, 137,  
139, 142, 157, 170, 201, 233,  
253  
market capitalization, 27, 131, 148.  
*See also* equity value  
market conditions, 11, 18, 52–53, 71,  
76, 93–95, 106, 172, 176–177,  
184–187, 190, 213, 236, 253,  
276

- marketing materials, 165, 167, 252, 256–257, 259–261. *See also* confidential information memorandum (CIM) and teaser
- market risk premium, 128–129, 147–148
- market share, 34, 48, 117, 169–170, 253
- market value, 38, 109, 125, 130, 147
- material adverse change/effect (MAC/MAE), 274, 276
- maturity, 166, 182–185, 188, 190, 191, 192, 199, 218, 222
- MBO. *See* management buyout
- MD&A. *See* management discussion & analysis
- merchant banking, 163
- merger, 193–194, 274, 276. *See also* one-step merger and two-step tender process
- merger of equals, 77
- merger proxy (PREM14A/DEFM14A), 20, 78, 82, 97
- mergers & acquisitions (M&A) transaction, 20, 23, 44, 71, 78, 80, 82, 279
- mezzanine debt/financing, 27, 165, 178, 184, 186–189
- mid-cap, 65, 69
- mid-year convention/discounting, 133–135, 151, 155
- minority interest, 32. *See also* noncontrolling interest
- Moody's Investors Service, 19, 21, 24, 39, 55, 178
- monetization, 176–177, 232
- MSCI Barra. *See* Barra
- multiples. *See* trading multiples and transaction multiples
- N**
- NAICS. *See* North American Industry Classification System
- NASDAQ, 55, 78
- NC. *See* non-callable
- negative covenants, 193–194
- negotiated sale, 76, 251, 253, 281–282 advantages and disadvantages, 282
- negotiations, 123, 196, 251–252, 254, 256, 262–263, 268, 273, 276–278, 282
- net debt, 32, 36, 38, 50–51, 58, 62–63, 85, 89, 102, 136, 154, 207, 233
- net income, 13, 18, 21, 25, 27, 30, 32, 34–36, 42–45, 50, 89–90, 93, 104, 194, 199, 203–204, 213, 215, 222, 224, 226
- net income margin, 27, 35, 45
- net interest expense, 224
- net operating profit after taxes (NOPAT) 19, 36, 119. *See also* EBIAT
- net present value (NPV), 171–172. *See also* present value
- net share settlement (NSS), 28, 31–32
- net working capital (NWC), 109, 118 projection of, 121–124, 143–145
- New York Stock Exchange, 78
- non-callable, 191
- noncontrolling interest, 32, 38, 89, 136
- non-investment grade, 39, 178, 183–184. *See also* high yield bonds
- non-recurring items, 13, 22–23, 27, 36, 55, 98 adjusting for, 41–43, 51, 60–61, 80, 89, 102–104, 115, 199, 205
- non-solicitation, 262
- NOPAT. *See* net operating profit after taxes
- normalized basis/level, 41–42, 53, 89, 111, 115, 117, 132, 199, 260
- North American Industry Classification System (NAICS), 20–21, 53, 75

- notes to the financials, 42, 55, 97, 119  
NPV. *See* net present value  
NSS. *See* net share settlement  
NWC. *See* net working capital
- O**
- offer price per share, 82, 85–91,  
96–97, 101, 207  
offer price per share-to-LTM EPS, 90,  
93, 104–105  
Offer to Purchase, 78  
offer value, 82, 277. *See also* equity  
purchase price  
offering memorandum, 167  
OneSource, 23  
one-step merger, 78, 279–280  
operating company (OpCo), 177,  
189–190  
operating income/profit, 34, 118  
operating scenarios, 118, 195,  
198–199, 230, 237  
options. *See* stock options  
organic growth, 19, 169, 173,  
176–177  
organization and preparation stage, of  
auction, 256–262  
out-of-the-money, 30, 58, 83  
outliers, 13, 24, 48–49, 65, 73, 92
- P**
- par value, 31, 127, 146, 191, 194  
parent company, 79, 168  
*pari passu*, 183, 189, 194  
payment-in-kind (PIK) interest,  
185–187, 222  
PE firms. *See* private equity firms  
P/E ratio. *See* price-to-earnings ratio  
pension contracts, 265  
pension funds, 163, 166  
performance drivers, 110, 112,  
114–115, 140  
peripheral comparables, 13, 49  
permitted disclosures, 262  
perpetuity growth method (PGM),  
111, 132–133, 135, 151–152  
perpetuity growth rate, 112, 132–133,  
137, 151–152  
implied, 133, 151, 157  
PGM. *See* perpetuity growth method  
PIK. *See* payment-in-kind interest  
PP&E. *See* property, plant, and  
equipment  
PRE14A. *See* proxy statement  
precedent transactions analysis, 20,  
51, 71–109, 112, 138, 157, 207,  
236, 253, 258, 278, 281. *See also*  
Contents, page viii  
key pros and cons, 94  
pre-closing commitments, 273–274  
preemptive bid, 281  
preferred stock, 32, 38, 89, 136,  
178–179, 193  
PREM14A. *See* merger proxy  
premium paid, 71, 73, 77, 81, 89–91,  
94–95, 97–98, 105, 108, 253  
prepaid expenses, 121, 123–124, 145  
prepayments, 184, 191, 193–194  
present value, 109, 111–112, 124,  
131, 134, 139, 153, 253  
press release excerpts  
all-cash transaction, 85, 97  
announced synergies, 92  
cash and stock transaction, 88  
floating exchange ratio, 87  
fixed exchange ratio, 86  
press releases, 13, 15, 21–22, 24–25,  
40, 44, 55, 57, 62, 80–81, 83, 91,  
96, 101  
price-to-earnings (P/E) ratio, 11,  
44–45, 49–51, 64, 90, 105  
prime funds, 166  
prime rate, 181  
prior stub, 40  
priority status, 182, 189  
private acquirers, 79, 81  
private equity (PE) firms, 163  
privately held companies, 15  
private placement. *See* Rule 144A  
private targets, 20, 77–78, 80–81,  
251, 272

- pro forma  
accretion/(dilution) analysis, 267  
balance sheet, 44, 201, 203–204,  
209, 212, 215, 224–226  
cash flow statement, 215–216,  
226–229  
compliance, 194  
income statement, 215, 222–224  
financial data, 23, 30, 44, 78–80,  
198–199, 204, 230, 253, 279,  
281  
products (and services), 16–18,  
33–34, 53, 114, 122–123, 169,  
253  
profitability, 13, 16, 19, 27, 34–35,  
46, 48, 62, 65, 114, 116, 170,  
176–177  
projection period, 109, 111, 115–122,  
124, 126, 131–135, 139–143,  
145, 175, 195, 199, 203,  
205–206, 209, 213, 216, 218,  
221–222, 224, 226, 228, 230,  
232–233  
property, plant, and equipment  
(PP&E), 119–120, 170, 182,  
188, 203–206, 212  
pro-rata  
bank debt, 183  
repayment, 221  
prospective buyers, 16, 77, 164, 169,  
196, 198, 251–252, 254,  
256–263, 265–267, 270–273,  
276–277, 281  
prospectus (424B), 30, 44. *See also*  
registration statement  
proxy statement, 20, 23, 25, 28, 53,  
78–82, 97, 101, 279  
public acquirers, 72, 78–80, 91, 95,  
279  
public targets, 77–79, 82, 89–90, 96,  
198, 251, 262, 278  
publicly traded companies, 15, 21,  
109, 114, 116, 130, 136, 154,  
169  
purchase consideration, 76–81,  
85–88, 98, 100, 186, 272  
purchase price, 20, 44, 71–72, 76–79,  
81, 89, 91–92, 97, 161–162, 164,  
172–173, 175, 177–179, 181,  
185, 187, 196, 198, 212, 232,  
235–237, 251, 263, 267–268,  
272, 277, 281  
assumptions, 206–207  
purchase/sale agreement, 23, 78, 255.  
*See also* definitive agreement
- Q**  
qualified institutional buyers (QIBs),  
79, 185  
quarterly report. *See* Form 10-Q
- R**  
ranking  
capital structure, 178, 180, 184,  
186  
relative to peers, 13, 48  
rating agencies, 19, 21, 25, 39, 55.  
*See also* Fitch Ratings, Moody's,  
and S&P  
Ratio Test, 194  
redemptions, 191, 193  
refinanced, 44, 85, 191, 199, 209, 213  
refinancing, 88, 162, 177, 221  
registration statement, 44, 78–80,  
82–83, 185  
Regulation FD (fair disclosure) 15,  
23, 259  
regulatory approvals, 255, 272,  
274–275, 278–279  
reinvestment risk, 191  
reported income statement, 42–43,  
59–60, 102–103  
reporting period, 22, 43–44, 114  
representations and warranties, 181,  
273–276  
restricted payments, 177, 193–194  
restructuring charges, 41–43, 60–61  
restructurings, 11, 71, 109, 171, 195  
return on assets (ROA), 19, 27, 37,  
62  
return on equity (ROE), 19, 27,  
36–37, 62

- return on invested capital (ROIC), 19, 27, 36, 62  
return on investment (ROI), 19, 27, 36–37, 62–63  
revenues, 17, 116. *See also* sales  
revolver availability, 181, 280  
revolving credit facilities (revolver), 127, 165, 180–184, 190, 192, 201, 209, 213, 215–216, 218, 221–222  
risk-free rate, 127–129, 147–148  
ROA. *See* return on assets  
roadshow, 166–167  
ROE. *See* return on equity  
ROI. *See* return on investment  
ROIC. *See* return on invested capital  
rolled equity, 178–179, 187  
roll-up, 164, 169  
Rule 144A, 79, 185  
Rule 424, 44
- S**
- sale process, 16, 23, 53, 77–78, 89, 116, 164, 198, 201, 235, 251–282. *See also* Contents, page xi  
sales, 18, 25, 33–34  
    projection of, 116–117, 140–142  
Sarbanes-Oxley Act of 2002 (SOX), 168  
scale, 18, 34, 115, 162–170, 176  
Schedule 13E-3, 79, 82  
Schedule 14A. *See* proxy statement  
Schedule 14D-9, 78, 82  
Schedule TO, 78–79, 82–83  
screening  
    for comparable companies, 20–21, 53–54  
    for comparable acquisitions, 75–77, 95  
SEC. *See* Securities and Exchange Commission  
SEC filings, 13, 15–16, 21–24, 34, 36, 44, 54–55, 57, 79, 81–82, 89, 96, 110, 114, 140, 198, 278  
second lien, 178, 182, 185, 189, 191  
second lien term loans, 184  
second priority interest. *See* second lien  
second round, of auction, 256, 262–267, 270–276  
sector, 11, 15–23, 27–28, 34, 47, 49, 52–53, 69, 72, 75, 92–93, 95, 105–106, 109–111, 114–117, 121–122, 126, 132, 140, 164, 166, 169, 177, 198, 201, 253, 259–260, 263, 267, 270  
sector coverage, 195, 198  
sector-specific multiples, 44, 46–47  
Securities Act of 1933, 79, 167, 181, 185  
Securities and Exchange Commission (SEC), 13  
Securities Exchange Act of 1934, 13, 167, 181  
security, 162, 182, 188, 214  
selling, general & administrative (SG&A), 34–35, 119  
    projection of, 117–118, 142  
sell-side advisory, 116, 162, 164, 196, 198, 236, 251–252, 255–259, 261–268, 270, 272, 276–278, 281–282  
senior (ranking), 50, 187–189, 194  
senior secured, 38, 180, 185, 189–190, 193, 209, 213, 230.  
    *See also* first lien and second lien  
senior subordinated, 178, 185, 189–190, 194, 221–222  
senior unsecured, 178, 185, 189–190  
seniority, 162, 188–190, 215  
sensitivity analysis  
    DCF analysis, 109, 112, 132, 137–138, 149–150, 156–157  
    LBO analysis, 196, 233–236  
SG&A. *See* selling, general & administrative  
share price, 24–25, 27–31, 37, 44–45, 50, 55, 58, 62, 64, 82, 85–87, 90–91, 105–106, 111  
    accretion/(dilution) analysis, 267  
    implied, 50, 136–137, 154

- share price (*Continued*)
    - performance benchmarking, 278
    - systematic risk, 127
    - unaffected, 89–91, 98, 105
  - shareholder approval, 255, 275, 278–280
  - shareholder vote, 78, 82
  - shareholders' equity, 19, 25, 32, 36, 62–63, 206, 211–213, 215, 224, 226, 230
  - short-form LBO model, 203
  - SIC. *See* Standard Industrial Classification system
  - size, of company, 13, 15–16, 18, 21, 27, 45–46, 48–49, 65, 79, 95, 126, 131, 169, 176, 253, 258, 270, 278, 282
    - key financial data, 33–39
    - market valuation, 27–33
  - size premium (SP), 131, 148
  - small-cap, 65, 69
  - sources and uses of funds, 203, 206, 208–210, 212, 214, 218, 222, 237
  - sovereign wealth funds, 163
  - SOX. *See* Sarbanes-Oxley Act of 2002
  - SP. *See* size premium
  - S&P. *See* Standard & Poor's
  - S&P 500, 129
  - SPACs. *See* special purpose acquisition companies
  - special dividends, 274
  - special purpose acquisition companies (SPACs), 163
  - Sponsor Case/Model, 201
  - sponsors. *See* financial sponsors
  - spreading, 12
    - comparable companies, 13, 23, 25–47, 55–64
    - precedent transactions, 72–73, 78, 81–92, 98–105
  - springing financial covenant, 182–183
  - standalone, 91, 198, 267–268, 281
  - Standard & Poor's (S&P), 19, 21, 24, 39, 55, 178
  - Standard & Poor's Leveraged Commentary & Data Group, 179
  - Standard Industrial Classification (SIC) system, 20–21, 53, 75
  - standstill agreement, 262
  - stapled financing, 164, 256, 258, 262, 265–267
  - state law, 78, 279
  - steady state, 111, 115–116, 118, 120, 131
  - stock-for-stock transaction, 85–88, 274
  - stock options, 22, 25, 27–31, 50, 54, 57–58, 80, 83, 101, 136, 274
  - stock price. *See* share price
  - stock sale transaction, 212, 274, 276
  - straight-line depreciation, 119
  - strategic alternatives, 90, 98, 105, 251
  - strategic buyers, 71, 76–77, 91, 95, 177, 196, 235–236, 251–252, 258–260, 262–263, 267–268, 270, 272, 281–282
  - strategic fit, 254, 258, 281
  - strike price. *See* exercise price
  - structural protections, 87
  - structural subordination, 189–190
  - stub period, 141
  - subordination provisions, 189
  - subprime mortgage crisis, 109, 161, 179, 216
  - sub-sector, 13, 15–17, 49
  - sum of the parts, 124
  - super-priority, 192
  - suppliers, 17, 34, 110, 114, 124, 140, 170, 254, 258, 260, 265, 272, 282
  - syndication, 165, 183, 192
  - synergies, 71, 73, 76–77, 80–81, 87, 89, 91–92, 98, 177, 236, 253, 258–259, 268, 270, 281
  - systematic risk, 127, 129
- T
- tangible assets, 120, 182, 212, 269
  - tangible value, 91, 167

- target management, 163, 166–167, 171, 187, 252, 257, 260, 262, 270
  - targeted auction, 251–252, 254, 257, 265
    - advantages and disadvantages, 254
  - tax deductibility, 126–127, 161, 174, 212
  - tax expense, 34, 42
    - projection of, 119, 143
  - tax regime, 11, 34
  - taxable event, 85
  - T-bills, 128
  - T-bonds, 128
  - teaser, 259–262
    - sample, 260
  - tender premium, 191
  - tender offer, 78–79, 81–82, 279–280
  - tenor. *See* maturity
  - term. *See* maturity
  - term loan A, 183, 221
  - term loan B, 183–184, 209–210, 221
  - term loan facilities, 183–184
  - terminal value, 109–112, 114, 117, 124, 131–135, 138–139, 151–153, 157, 253
  - terminal year, 111, 117, 131–133, 151
  - termination fee. *See* breakup fee
  - termination provisions, 273, 275
  - terms, of LBO financing, 167, 188–194
  - third lien, 185, 187
  - Thomson Reuters, 20–21, 23–24, 81, 129
  - Thomson Reuters SDC Platinum, 75, 180
  - tiering, 13, 18, 49, 131
  - time value of money, 134, 172, 233
  - T-notes, 128
  - toggle cells/function, 116, 198, 201, 207, 237
  - total interest expense, 222, 224
  - trading comps. *See* comparable companies analysis
  - trading liquidity, 18, 184
  - trading multiples, 11–13, 19, 23, 25, 27, 40, 44, 48–49, 55, 62, 64–65, 253
    - terminal value, 132–133, 135, 151
  - trailing multiples, 64
  - trailing twelve months (TTM). *See* last twelve months
  - transaction comps. *See* precedent transactions analysis
  - transaction multiples, 71–73, 78, 80–81, 89, 91–92, 94, 98, 104–105
  - transaction rationale, 80, 96
  - transaction structure, 206, 230, 251, 273–274
  - transaction value, 82–89
  - treasury stock method (TSM), 28–29, 31, 50, 57, 82, 101
  - triggering event, 22
  - TSM. *See* treasury stock method
  - two-step tender process, 280
- U**
- underwriters, 162, 165, 167, 201, 213, 230
  - underwritten financing, 165
  - undrawn, 181, 209, 218
  - unlevered beta, 130, 147–148
  - unlevered free cash flow, 133, 161
  - unsecured, 185, 188
  - unsecured claims, 184
  - unsecured creditors, 182, 188
  - unsecured term loan, 186
  - unsystematic risk, 128
  - useful life, 119–120
  - uses of funds. *See* sources and uses of funds
- V**
- valuation
    - comparable companies, determination in, 13–15, 49–51, 69
    - DCF analysis, determination in, 111–112, 135–138, 153–157

- valuation (*Continued*)
  - LBO analysis, determination in, 235–236
  - precedent transactions, determination in, 73, 93, 106–108
  - valuation analysis, in sale process, 256–257, 260, 263, 278
  - valuation floor, 267
  - valuation paradigm, 253
  - value maximization, 77, 251, 254
  - variable costs, 35, 118
  - venture capital funds, 163
  - vesting period, 27
- W**
- WACC. *See* weighted average cost of capital
- Wall Street, 11, 34, 129, 141
- warrants, 22, 25, 27–29, 54, 57–58, 80, 83, 101, 136, 187
- weighted average cost of debt, 127
- weighted average cost of capital (WACC), 109–111, 114, 124–135, 137–139, 146, 149–151, 153, 157
- weighted average diluted shares outstanding, 43
- weighted average exercise (strike) price, 28, 50, 57–58, 83, 101
- working capital. *See* net working capital (NWC)
- write-down, 41–43
- write-up, 212
- Y**
- year-end discounting, 133, 135, 152–153
- year-over-year (YoY)
  - balance sheet accounts, changes in, 204
  - growth rates, 141
  - NWC, changes in, 122, 145, 204
- year-to-date (YTD), 22, 40, 54, 102
- yield-to-call (YTC), 127
- yield-to-worst call (YTW), 127



Investing's **Greatest Minds**  
Put The Markets In **Perspective**

**The Journal of Portfolio Management** maintains its pre-eminent position as the foremost source of analysis and research on effective strategies for portfolio management— for over 30 years.

**Subscribers receive:**

- Incisive analysis from leading experts and academics on how to maximize and achieve your portfolio strategy effectively.
- Clearly illustrated articles on critical issues including hedging, derivatives, market timing and currency risk.
- Detailed models that you can use to strategically manage your portfolio and beat the benchmarks.

**4 Easy Ways to Order:**

Call Hotline: 1-800-437-9997  
(outside US: +1-212-224-3570)

Email: [info@iijournals.com](mailto:info@iijournals.com)

Fax: +1-212-224-3553

Sign up at: <http://www.iiJPM.com>



*The Voices of Influence*

FOR MORE INFORMATION VISIT  
[www.iiJPM.com](http://www.iiJPM.com)

<http://www.pbookshop.com>

<http://www.pbookshop.com>

<http://www.pbookshop.com>

<http://www.pbookshop.com>

<http://www.pbookshop.com>

<http://www.pbookshop.com>

<http://www.pbookshop.com>